Display options
Cite
Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153-161doi: 10.1007/s13539-011-0034-6.
Dalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., Morton, R. A., & Steiner, M. S. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Journal of cachexia, sarcopenia and muscle, 2(3), 153-161. https://doi.org/10.1007/s13539-011-0034-6
Dalton, James T, et al. "The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial." Journal of cachexia, sarcopenia and muscle vol. 2,3 (2011): 153-161. doi: https://doi.org/10.1007/s13539-011-0034-6
Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161. doi: 10.1007/s13539-011-0034-6. Epub 2011 Aug 02. PMID: 22031847; PMCID: PMC3177038.
Copy Download .nbib Format: NLM
Share it on

J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161. doi: 10.1007/s13539-011-0034-6. Epub 2011 Aug 02.

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

Journal of cachexia, sarcopenia and muscle

James T Dalton, Kester G Barnette, Casey E Bohl, Michael L Hancock, Domingo Rodriguez, Shontelle T Dodson, Ronald A Morton, Mitchell S Steiner

Affiliations

  1. GTx, Inc., 175 Toyota Plaza, Memphis, TN 38103 USA.

PMID: 22031847 PMCID: PMC3177038 DOI: 10.1007/s13539-011-0034-6

Abstract

BACKGROUND: Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease, and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men. GTx-024 has demonstrated promising pharmacologic effects in preclinical studies and favorable safety and pharmacokinetic profiles in phase I investigation. METHODS: A 12-week double-blind, placebo-controlled phase II clinical trial was conducted to evaluate GTx-024 in 120 healthy elderly men (>60 years of age) and postmenopausal women. The primary endpoint was total lean body mass assessed by dual energy X-ray absorptiometry, and secondary endpoints included physical function, body weight, insulin resistance, and safety. RESULTS: GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant (P < 0.001, 3 mg vs. placebo) and clinically meaningful. There were also significant improvements in physical function (P = 0.013, 3 mg vs. placebo) and insulin resistance (P = 0.013, 3 mg vs. placebo). The incidence of adverse events was similar between treatment groups. CONCLUSION: GTx-024 showed a dose-dependent improvement in total lean body mass and physical function and was well tolerated. GTx-024 may be useful in the prevention and/or treatment of muscle wasting associated with cancer and other chronic diseases.

References

  1. JAMA. 1989 Feb 24;261(8):1165-8 - PubMed
  2. Am J Cardiovasc Drugs. 2007;7(3):219-24 - PubMed
  3. J Clin Endocrinol Metab. 1961 Nov;21:1440-7 - PubMed
  4. Am J Clin Nutr. 2002 Aug;76(2):473-81 - PubMed
  5. J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):7-8 - PubMed
  6. Endocrinology. 2005 Dec;146(12):5444-54 - PubMed
  7. Am J Kidney Dis. 2001 Dec;38(6):1337-42 - PubMed
  8. N Engl J Med. 2010 Jul 8;363(2):109-22 - PubMed
  9. Aging Male. 2007 Jun;10(2):53-6 - PubMed
  10. J Med Chem. 2004 Jul 15;47(15):3765-76 - PubMed
  11. J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):1-5 - PubMed
  12. J Intern Med. 2006 Jun;259(6):553-60 - PubMed
  13. Nat Clin Pract Endocrinol Metab. 2006 Mar;2(3):146-59 - PubMed
  14. Endocrinol Metab Clin North Am. 2007 Jun;36(2):365-77 - PubMed
  15. Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):400-7 - PubMed
  16. Am J Epidemiol. 1998 Apr 15;147(8):755-63 - PubMed
  17. N Engl J Med. 1996 Jul 4;335(1):1-7 - PubMed
  18. Nat Clin Pract Urol. 2006 Dec;3(12):653-65 - PubMed
  19. Age Ageing. 2004 Nov;33(6):548-55 - PubMed
  20. J Sex Med. 2007 Jul;4(4 Pt 1):1046-55 - PubMed
  21. Am J Clin Nutr. 2010 Apr;91(4):1123S-1127S - PubMed
  22. Cancer. 2001 Sep 15;92(6 Suppl):1669-77 - PubMed
  23. Pharm Res. 2006 Aug;23(8):1641-58 - PubMed
  24. Am J Hypertens. 2005 Apr;18(4 Pt 2):106S-111S - PubMed
  25. Nutr Rev. 2003 May;61(5 Pt 1):157-67 - PubMed
  26. Am J Med. 1980 Oct;69(4):491-7 - PubMed
  27. Arch Intern Med. 2007 Mar 26;167(6):551-61 - PubMed
  28. Clin Endocrinol (Oxf). 1984 Aug;21(2):97-107 - PubMed
  29. BMJ. 1997 Nov 8;315(7117):1219-22 - PubMed
  30. Curr Opin Nephrol Hypertens. 2006 Jul;15(4):361-5 - PubMed
  31. J Pharmacol Exp Ther. 2005 Oct;315(1):230-9 - PubMed
  32. Lancet Oncol. 2008 Jul;9(7):629-35 - PubMed
  33. J Med Chem. 2009 Jun 25;52(12):3597-617 - PubMed
  34. Arch Phys Med Rehabil. 2007 May;88(5):604-9 - PubMed
  35. Eur J Clin Nutr. 2000 Jun;54 Suppl 3:S40-7 - PubMed
  36. J Clin Endocrinol Metab. 1999 Oct;84(10):3459-62 - PubMed
  37. J Am Geriatr Soc. 2008 Nov;56(11):2118-23 - PubMed
  38. Diabetologia. 1985 Jul;28(7):412-9 - PubMed
  39. Int J Biochem Cell Biol. 2005 May;37(5):1084-104 - PubMed
  40. N Engl J Med. 1995 Mar 2;332(9):556-61 - PubMed

Publication Types